RE:Pelareorep in 3rd line HR+/HER2 negative breast cancerSeptember 30, 2024 - Roche/Genentech is beginning to turn on its acquistion tap with an $850 million upfront for Regor Pharmaceuticals’ Phase 1 portfolio of CDK inhibitors, taking ownership of a breast cancer candidate (RGT-419B) that has shown signs of single-agent efficacy in patients failed by existing options.
ONCY is demonstrating pelareorep's single agent effectiveness in breast cancer and is synergistic with small molecules suich as CDK inhibitors.
https://www.fiercebiotech.com/biotech/genentech-inks-850m-upfront-deal-regors-cdk-inhibitors-furthering-breast-cancer-expansion